ES2192190T3 - Fragmentos proteicos tensioactivos pulmonares. - Google Patents

Fragmentos proteicos tensioactivos pulmonares.

Info

Publication number
ES2192190T3
ES2192190T3 ES93905865T ES93905865T ES2192190T3 ES 2192190 T3 ES2192190 T3 ES 2192190T3 ES 93905865 T ES93905865 T ES 93905865T ES 93905865 T ES93905865 T ES 93905865T ES 2192190 T3 ES2192190 T3 ES 2192190T3
Authority
ES
Spain
Prior art keywords
pulmonary
tensioactive
fragments
proteic fragments
proteic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93905865T
Other languages
English (en)
Inventor
Madhup Krishna Dhaon
Edwin Orville Lundell
Virender Kumar Sarin
Constance Hope Baxter
Darryl Robin Absolom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2192190T3 publication Critical patent/ES2192190T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

ESTA INVENCION DESCRIBE QUE CIERTOS FRAGMENTOS DE UNA PROTEINA DE SURFACTANTE PULMONAR EXHIBE INESPERADA ACTIVIDAD SUPERFICIAL. ESTOS FRAGMENTOS DE PROTEINA SON USADOS EN FORMULACIONES DE PREPARACION PARA EL TRATAMIENTO DE SINDROME DE AGOTAMIENTO RESPIRATORIO.
ES93905865T 1992-04-10 1993-02-09 Fragmentos proteicos tensioactivos pulmonares. Expired - Lifetime ES2192190T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86691692A 1992-04-10 1992-04-10

Publications (1)

Publication Number Publication Date
ES2192190T3 true ES2192190T3 (es) 2003-10-01

Family

ID=25348718

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93905865T Expired - Lifetime ES2192190T3 (es) 1992-04-10 1993-02-09 Fragmentos proteicos tensioactivos pulmonares.

Country Status (8)

Country Link
US (2) US5547937A (es)
EP (1) EP0635028B1 (es)
AT (1) ATE231522T1 (es)
AU (1) AU3662593A (es)
DE (1) DE69332654T2 (es)
ES (1) ES2192190T3 (es)
TW (1) TW240170B (es)
WO (1) WO1993021221A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020307A (en) * 1997-04-25 2000-02-01 Ony, Inc. Compositions and methods for isolating lung surfactant hydrophobic proteins SP-B and SP-C
US6013764A (en) 1996-07-17 2000-01-11 Ortho Pharmaceutical Corp. Liquid phase peptide synthesis of KL-4 pulmonary surfactant
US5958902A (en) * 1997-04-16 1999-09-28 Wisconsin Alumni Research Foundation Method and composition for treating sleep apnea
WO2001039573A2 (de) * 1999-12-01 2001-06-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Verwendung von lungensurfactant zur behandlung von legionärskrankheit
US6660833B1 (en) * 2000-02-29 2003-12-09 Harbor-Ucla Research And Education Institute Respiratory distress syndrome therapy with peptide analogs of human SP-B
US7582312B2 (en) 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
WO2006074296A1 (en) 2005-01-06 2006-07-13 Discovery Laboratories, Inc. Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia
CA2606688A1 (en) * 2005-05-03 2006-11-09 Ross Allen Ridsdale Phospholipid formulations and uses thereof in lung disease detection and treatment
PT103484B (pt) * 2006-05-19 2008-03-31 Univ Do Minho Formulação com domínios de ligação hidrófobos e domínios de ligação a hidratos de carbono para aplicações cosméticas nomeadamente para tratamento de fibras queratinosas como o cabelo.
WO2008036293A1 (en) * 2006-09-19 2008-03-27 Discovery Laboratories, Inc. Pulmonary surfactant formulations and methods for promoting mucus clearance
CN101754747A (zh) * 2007-06-05 2010-06-23 Paka肺部医药公司 用于向肺脏递送药物的方法以及组合物
US9289388B2 (en) 2008-12-10 2016-03-22 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
WO2013188016A2 (en) 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4234475A (en) * 1975-08-15 1980-11-18 The Gillette Company Reacting protein with organic acid
US5055553A (en) * 1985-09-26 1991-10-08 Genetics Institute Inc. Low molecular weight pulmonary surfactant proteins
WO1988003170A1 (en) * 1986-10-24 1988-05-05 Whitsett Jeffrey A Pulmonary hydrophobic surfactant-associated proteins
JPH01501282A (ja) * 1986-12-08 1989-05-11 ホイツトセツト，ジエフリー　エイ． 肺胞疎水性界面活性物質関連タンパク質
US5164369A (en) * 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
US5238920A (en) * 1989-08-22 1993-08-24 Abbott Laboratories Pulmonary surfactant protein fragments
EP0458167B1 (en) * 1990-05-21 1997-04-23 Abbott Laboratories Fatty acid-pulmonary surfactant conjugates
EP0587799B1 (en) * 1991-05-23 1999-07-07 Merrell Pharmaceuticals Inc. Inhibitors of cathepsin g and elastase for preventing connective tissue degradation

Also Published As

Publication number Publication date
AU3662593A (en) 1993-11-18
WO1993021221A1 (en) 1993-10-28
EP0635028A1 (en) 1995-01-25
ATE231522T1 (de) 2003-02-15
DE69332654D1 (de) 2003-02-27
EP0635028B1 (en) 2003-01-22
US5547937A (en) 1996-08-20
DE69332654T2 (de) 2003-09-25
US5753621A (en) 1998-05-19
EP0635028A4 (en) 1995-11-22
TW240170B (es) 1995-02-11

Similar Documents

Publication Publication Date Title
ES2192190T3 (es) Fragmentos proteicos tensioactivos pulmonares.
NO20012787D0 (no) GLP-1 analoger
AR028512A1 (es) Composiciones antimicrobianas acidas para el tratamiento de alimentos y superficies que contactan alimentos y metodos para la utilizacion de estas
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
HN2002000153A (es) Formulaciones autoemulsionantes de inhibidores de la proteina de transferencia de colesteril ester.
ATE282635T1 (de) Glp-1 analoge
AR030068A1 (es) Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet
TR200102308T2 (tr) Yüzey etkinliğine sahip yapay peptidler ve bunların yapay yüzey aktif maddelerin hazırlanmasında kullanımı
ATE435661T1 (de) Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
DE60224508D1 (de) Wti-modifiziertes peptid
ID24520A (id) Analog-analog peptida lh-rh, penggunaannya dan komposisi farmasi yamg mengandungnya
PT755249E (pt) Utilizacao de inibidores da reaccao de maillard para o tratamento de doenca com base em amiloidose
MX18106A (es) Compuesto amidinicos y composiciones usadas para el tratamiento de pneumonia por pneumocystis carinii y otras enfermedades.
MX9300558A (es) Nueva sulfonilurea, procedimiento para su preparacion y formulado farmaceutico que la contiene.
DE69626987D1 (de) Pharmaceutische komposition
ES2135254T3 (es) Procedimiento para la degradacion de quinolonas y naftiridonas.
NO20032597L (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
NO993360L (no) Anvendelse av pramipeksol ved behandling av "restless leg"- syndromet
MX2022013195A (es) Uso de proteina surfactante d para tratar infecciones virales.
PT1187612E (pt) Utilizacao do riluzole para o tratamento da esclerose multipla
PT894500E (pt) Vacina para streptococcus equi
PT1276495E (pt) Utilizacao de tensioactivo pulmonar recombinante para o tratamento precoce de doencas pulmonares agudas
PT1173194E (pt) Sp-a recombinante para o tratamento ou a prevencao da infeccao e da inflamacao pulmonares
ES2127728T3 (es) Proteina superficial de kda de p. falciparum.
FI942938L (fi) Soijaproteiini tai -hydrolysaatit farmaseuttisissa koostumuksissa bioaktiivisten peptidien suojana entsymaattista inaktivoitumista vastaan